Top Page
Rubicon Organics
(ROMJ)
Rubicon Organics (ROMJ) vs. iShares MSCI Canada ETF (EWC)
Rubicon Organics Business Overview & Revenue Model
Rubicon Organics Earnings Call Summary
Rubicon Organics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.06M | 48.70M | 40.12M | 35.52M | 22.61M | 9.39M |
| Gross Profit | 19.12M | 15.42M | 13.14M | 13.81M | 1.51M | -663.96K |
| EBITDA | 4.43M | 1.86M | 1.95M | 217.00K | -10.87M | -10.37M |
| Net Income | 235.28K | -2.56M | -1.82M | -3.86M | -14.52M | -14.98M |
Balance Sheet | ||||||
| Total Assets | 62.03M | 56.61M | 54.89M | 56.11M | 54.84M | 51.07M |
| Cash, Cash Equivalents and Short-Term Investments | 7.28M | 9.86M | 10.91M | 8.29M | 11.58M | 12.14M |
| Total Debt | 9.51M | 9.89M | 10.40M | 10.22M | 9.82M | 13.99M |
| Total Liabilities | 19.19M | 19.21M | 17.00M | 17.77M | 15.94M | 22.23M |
| Stockholders Equity | 42.84M | 37.40M | 37.89M | 38.33M | 38.90M | 28.84M |
Cash Flow | ||||||
| Free Cash Flow | -3.64M | 1.85M | 2.32M | -2.50M | -15.94M | -20.30M |
| Operating Cash Flow | 3.02M | 3.40M | 5.05M | 1.95M | -10.44M | -14.31M |
| Investing Cash Flow | -6.66M | -1.55M | -2.73M | -4.45M | -5.50M | 3.08M |
| Financing Cash Flow | 1.42M | -1.77M | -804.01K | -838.56K | 15.30M | 21.26M |
Rubicon Organics Technical Analysis
Rubicon Organics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $77.85M | 5.19 | 22.76% | ― | -0.53% | ― | |
61 Neutral | C$63.13M | ― | -20.91% | ― | 36.50% | -306.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $33.25M | 183.33 | 0.61% | ― | 34.19% | ― | |
49 Neutral | C$55.94M | ― | -10.63% | ― | 21.71% | 18.75% | |
45 Neutral | $28.86M | -18.28 | -109.32% | ― | 2.00% | 80.83% | |
44 Neutral | C$21.82M | ― | -15.75% | ― | 26.75% | 61.79% |
Rubicon Organics Corporate Events
Rubicon Organics announced it will release its Q3 2025 financial results on November 12, 2025, followed by a conference call on November 13, 2025. The company is expanding its production capacity by over 40% with the acquisition of the Cascadia facility, supporting its growth in the premium cannabis segment. Rubicon’s focus on quality and innovation has driven consistent revenue growth and positive Adjusted EBITDA, solidifying its position as a leader in the market.
The most recent analyst rating on (TSE:ROMJ) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics has released its fifth annual Environmental, Social, and Governance (ESG) Report, highlighting significant achievements in sustainable cannabis production. The report reveals a 410% increase in net revenue since 2020, with minimal increases in energy and water usage, showcasing the company’s commitment to resource efficiency. Employee engagement and pride are high, reflecting a strong corporate culture. The report underscores Rubicon’s leadership in ESG within the cannabis sector, aiming to be the most trusted house of premium cannabis brands.
The most recent analyst rating on (TSE:ROMJ) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics has received a Health Canada cultivation license for its Cascadia facility in Hope, BC, which will increase its production capacity by 40% and support revenue and EBITDA growth. This expansion will enable the company to meet demand for its premium products in Canada and explore international market opportunities. The company also renamed its facilities to reflect its West Coast culture and expanded focus. The new capacity is expected to drive growth in both domestic and export markets, reinforcing Rubicon’s position as a leader in the premium cannabis industry.
The most recent analyst rating on (TSE:ROMJ) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics announced its participation in two investor events, Small Cap Discoveries in Vancouver and the Planet MicroCap Showcase in Toronto, to present its achievements and future plans. The company has also engaged Atrium Research Corporation for research services, indicating a strategic move to enhance its market presence and investor relations. These developments are expected to strengthen Rubicon’s positioning in the premium cannabis segment and support its growth trajectory.
The most recent analyst rating on (TSE:ROMJ) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics’ Q2 2025 earnings call revealed a strong performance with record-breaking revenue growth, improved gross margins, and positive cash flow. The company is strategically expanding and innovating in its product offerings, which positions it well for future growth. However, challenges such as share erosion in topicals, licensing delays for a new facility, and inventory management remain.
Rubicon Organics Inc., a leading Canadian producer of premium organic cannabis, has reported its Q2 2025 financial results, showcasing significant growth and strategic advancements.
Rubicon Organics reported a record-breaking Q2 2025, with net revenue of $15.0 million, marking a 24% increase from the previous year, and a 30% rise in year-to-date revenue. The company achieved positive Adjusted EBITDA for the fifth consecutive quarter and expanded its production capacity by acquiring the Hope Facility, which will support future growth. The launch of new products, such as the 1964 Supply Co.™ All-in-One resin vapes, and strategic investments are expected to drive sustainable growth, enhancing Rubicon’s market position and offering value to stakeholders.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.
Rubicon Organics announced it will release its Q2 2025 financial results on August 18, 2025, and will host a conference call to discuss the results. The company continues to focus on premium quality and operational execution, which has led to consistent revenue growth and positive Adjusted EBITDA. The expansion of production capacity and strong brand equity position Rubicon Organics as a leader in the premium cannabis segment, with significant growth potential in the evolving Canadian market and increasing global demand.
The most recent analyst rating on (TSE:ROMJ) stock is a Buy with a C$1.10 price target. To see the full list of analyst forecasts on Rubicon Organics stock, see the TSE:ROMJ Stock Forecast page.